Cannara Biotech Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zohar Krivorot

Chief Executive Officer (CEO)

CA$300.0k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	5.4yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Zohar Krivorot en comparación con los beneficios de Cannara Biotech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Feb 29 2024	n/a	n/a	CA$6m
Nov 30 2023	n/a	n/a	CA$9m
Aug 31 2023	CA$300k	CA$300k	CA$7m
May 31 2023	n/a	n/a	CA$5m
Feb 28 2023	n/a	n/a	CA$3m
Nov 30 2022	n/a	n/a	CA$3m
Aug 31 2022	CA$75k	CA$75k	CA$2m
May 31 2022	n/a	n/a	CA$884k
Feb 28 2022	n/a	n/a	CA$1m
Nov 30 2021	n/a	n/a	CA$1m
Aug 31 2021	n/a	n/a	-CA$2m
May 31 2021	n/a	n/a	-CA$7m
Feb 28 2021	n/a	n/a	-CA$11m
Nov 30 2020	n/a	n/a	-CA$13m
Aug 31 2020	CA$92k	CA$92k	-CA$12m
May 31 2020	n/a	n/a	-CA$12m
Feb 29 2020	n/a	n/a	-CA$12m
Nov 30 2019	n/a	n/a	-CA$13m
Aug 31 2019	CA$150k	CA$150k	-CA$12m

Compensación vs. Mercado: La compensación total ($USD218.69K) de Zohar está en línea con el promedio de empresas de tamaño similar en el mercado Canadian ($USD177.17K).

Compensación vs. Ingresos: La compensación de Zohar ha aumentado más de un 20% en el último año.

CEO

Zohar Krivorot (47 yo)

5.4yrs

Permanencia

CA$300,000

Compensación

Mr. Zohar Krivorot serves as Chief Executive Officer of Cannara Biotech Inc. since 2019, Director since December 31, 2018 and is its Founder, Chairman of the Board. He served as President at Cannara Biotec...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zohar Krivorot	CEO & Chairman	5.4yrs	CA$300.00k	sin datos
Nicholas Sosiak	Chief Financial Officer	3.6yrs	CA$240.00k	0.027% CA$ 16.5k
Avi Krivorot	Chief Technology Officer	no data	CA$300.00k	0.052% CA$ 32.6k
Anthony Manouk	VP of Compliance & GM	no data	CA$160.00k	0.0049% CA$ 3.0k
Brian Sherman	General Counsel & VP Legal Affairs	no data	sin datos	0.019% CA$ 11.5k
David Abitbol	Vice President of Marketing	3.4yrs	sin datos	sin datos
Scott Carroll	Vice President of Marketing & Sales	no data	sin datos	0.0034% CA$ 2.1k
France Landry	Vice President of Human Resources	1.6yrs	sin datos	sin datos
Julia Bouvet	Chief of Staff	no data	sin datos	sin datos
Etienne Ledoux	Executive Officer	no data	CA$300.00k	sin datos

3.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de LOVE se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zohar Krivorot	CEO & Chairman	5.5yrs	CA$300.00k	sin datos
Jacob Kay	Independent Director	5.1yrs	CA$20.00k	0.24% CA$ 151.1k
Donald Olds	Independent Lead Director	3.6yrs	CA$32.50k	1.32% CA$ 818.1k
Derek Stern	Independent Director	5.5yrs	sin datos	0.42% CA$ 259.5k
Mary Durocher	Independent Director	4.1yrs	CA$17.50k	sin datos

5.1yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de LOVE se considera experimentada (5.1 años de antigüedad promedio).

Cannara Biotech Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Independent Director recently bought CA$60k worth of stock

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Independent Director recently bought CA$81k worth of stock

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad